Previous 10 | Next 10 |
home / stock / cmvlf / cmvlf news
Cellectis S.A. (CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 A.M. ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Bing Wang - Chief Financial Officer Conference Call Participants Gena ...
ALLO-316 was given Fast Track Designation for the treatment of patients with renal cell carcinoma. It is expected that the global kidney cancer market could reach $9.4 billion by 2026. ALLO-647 is a lymphodepletion agent that Allogene has developed to possibly help the expansion a...
Cellectis S.A. (CLLS) Q4 2021 Results Earnings Conference Call March 4, 2022, 08:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Bing Wang - Chief Financial Officer David Sourdive - Executiv...
Cellectis S.A. (CLLS) Q3 2021 Results Conference Call November 05 2021 08:00 AM ET Company Participants Andre Choulika - Chief Executive Officer Eric Dutang - Chief Financial Officer Carrie Brownstein - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
Cellectis S.A. (CLLS) Q2 2021 Earnings Conference Call August 6, 2021 08:00 AM ET Company Participants Eric Dutang - Chief Financial Officer André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Steve Doares - Senior Vice President, US Manufacturing Conferenc...
Cellectis S.A. (OTCPK:CMVLF): Q2 Non-GAAP EPS of $0.80; GAAP EPS of $0.88. Revenue of $14.62M (+216.5% Y/Y) beats by $3.07M. As of June 30, 2021, Cellectis, including Calyxt, had $257M in consolidated cash, cash equivalents, current financial assets and restricted cash of which $238M are attr...
Cellectis S.A. (CLLS) Q4 2020 Earnings Conference Call March 5, 2021 08:00 AM ET Company Participants Simon Harnest - Senior Vice President, Corporate Strategy and Finance André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dutang - Chief Financial Off...
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
Cellectis Romainville Ord Website:
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...